A COMPASS to REACH the right patients with thrombocardiology: benefits, risks, and future of the new concept

Juerg H Beer^{1

2}, Nicole Bonetti¹

Affiliations

¹ University of Zürich, Laboratory for Platelet Research, Molecular Cardiology, University of Zurich, Switzerland.
² Department of Internal Medicine, Cantonal Hospital of Baden, Switzerland.

Comment

Juerg H Beer et al. Eur Heart J. 2018.

. 2018 Mar 1;39(9):758-761.

doi: 10.1093/eurheartj/ehx702.

Juerg H Beer^{1

2}, Nicole Bonetti¹

¹ University of Zürich, Laboratory for Platelet Research, Molecular Cardiology, University of Zurich, Switzerland.
² Department of Internal Medicine, Cantonal Hospital of Baden, Switzerland.

No abstract available

Comment on

External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Darmon A, Bhatt DL, Elbez Y, Aboyans V, Anand S, Bosch J, Branch KR, Connolly SJ, Dyal L, Eikelboom JW, Fox KAA, Keltai K, Probstfield J, Yusuf S, Abtan J, Sorbets E, Eagle KA, Ducrocq G, Steg PG. Darmon A, et al. Eur Heart J. 2018 Mar 1;39(9):750-757a. doi: 10.1093/eurheartj/ehx658. Eur Heart J. 2018. PMID: 29186454